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Targeting Wide-Range Oncogenic Transformation
via PU24FCl, a Specific Inhibitor of Tumor Hsp90
regulatory alterations are cell specific, a drug targeting
one abnormality will be limited to use in only a subset
of cancers. Identifying the subset of responsive tumors
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Neal Rosen,1 Claudia Spampinato,2
Paul Modrich,2,3 and Gabriela Chiosis1,* has been difficult in clinical trial settings, and many
drugs have failed because of inadequate patient selec-1Program in Cell Biology and Department
of Medicine tion. Furthermore, the genetic plasticity of cancer cells
often permits rapid development of resistance, even inMemorial Sloan-Kettering Cancer Center
New York, New York 10021 patients who initially respond to targeted agents such
as Gleevec [5].2 Howard Hughes Medical Institute and
3 Department of Biochemistry It has been suggested that one potential way to cir-
cumvent this problem is to target the machinery thatDuke University Medical Center
Durham, North Carolina 27710 allows most cancer cells to function with the burden
of abnormalities they carry: the molecular chaperone
Hsp90 (see reviews [6, 7] by Neckers and Workman).
Hsp90 is required for the ATP-dependent refolding ofSummary
denatured or “unfolded” proteins and for the conforma-
tional maturation of a subset of proteins involved in theAgents that inhibit Hsp90 function hold significant
response of cells to extracellular signals. Activation ofpromise in cancer therapy. Here we present PU24FCl,
signaling pathways mediated by these Hsp90 clients isa representative of the first class of designed Hsp90
necessary for cell proliferation, regulation of cell cycleinhibitors. By specifically and potently inhibiting tumor
progression, and apoptosis. Additionally, gain-of-func-Hsp90, PU24FCl exhibits wide-ranging anti-cancer ac-
tion mutations responsible for transformation often re-tivities that occur at similar doses in all tested tumor
quire Hsp90 for maintenance of their folded, functionallytypes. Normal cells are 10- to 50-fold more resistant
active conformations. Tumor Hsp90 is present entirely into these effects. Its Hsp90 inhibition results in multiple
multi-chaperone complexes with high ATPase activity,anti-tumor-specific effects, such as degradation of
whereas Hsp90 from normal tissues is in a latent, un-Hsp90-client proteins involved in cell growth, survival,
complexed state, suggesting that tumor cells containand specific transformation, inhibition of cancer cell
Hsp90 complexes in an activated, high-affinity confor-growth, delay of cell cycle progression, induction of
mation that facilitates malignant progression [8].morphological and functional changes, and apoptosis.
These observations propose many potential clinicalIn concordance with its higher affinity for tumor Hsp90,
applications for agents that inhibit the chaperone activ-in vivo PU24FCl accumulates in tumors while being
ity of Hsp90. Unfortunately, currently reported Hsp90rapidly cleared from normal tissue. Concentrations
inhibitors have not yet lived up to the promise of theirachieved in vivo in tumors lead to single-agent anti-
target. Several natural products that have been identi-tumor activity at non-toxic doses.
fied as potently inhibiting Hsp90 (i.e., geldanamycin
(GM) [9], herbimycin [10], and radicicol (RD) [11]; FigureIntroduction
1) were restricted from clinical use because of in vivo
toxicity and/or instability issues [10, 12]. A less toxicHuman cancer is characterized by genetic instability
derivative of GM, 17-allylamino-17-demethoxygeldana-leading to the amplification or mutation of oncogenes.
mycin (17AAG) [13] (Figure 1), is currently in human clini-These genetic alterations may inhibit apoptosis, lead to
cal trials. This agent has activity in experimental tumordysregulated growth, or enhance metastatic potential.
models [14, 15], and early clinical data are encouraging.A number of genetic alterations responsible for the ma-
However, 17AAG has several limitations, such as limitedlignant phenotype have been identified, and a trend in
oral bioavailability and poor solubility. Furthermore, it iscancer therapy over the past 10 years has been to de-
puzzling that several tumor models, such as Rb-defec-velop agents that “target” a single molecular alteration.
tive tumors, which are sensitive to GM and RD, showThese efforts have led to the development of novel ther-
partial or total resistance to 17AAG (D.S., unpublishedapies such as Gleevec [1, 2] and Herceptin [3, 4], which
data). Moreover, the dose-limiting toxicity of 17AAG inhave been successful for the small fraction of patients
patients (liver toxicity) is likely attributable to the benzo-with tumors dependent on the oncoproteins they target.
quinone chemical structure of the compound and notHowever, because most tumors are characterized by
to inhibition of Hsp90 [16]. Efforts to improve the solubil-multiple growth regulatory alterations, targeting one ab-
ity and bioavailability of 17AAG are underway (i.e., 17-normality is insufficient. In addition, because the growth-
dimethylaminoethylamino-17-demethoxygeldanamy-
cin); however, the complex chemical structure of this
*Correspondence: chiosisg@mskcc.org class makes the search for derivatives with more drug-
4 These authors contributed equally to this work. like properties very difficult, and it is improbable that6 Present address: Department of Chemistry, University of Wiscon-
future efforts will eliminate the benzoquinone feature ofsin, Madison, Wisconsin 53706.
this compound without its losing activity.5 Present address: Department of Tumor Biology, Schering-Plough
Research Institute, Kenilworth, New Jersey 07033. Thus, the potential of Hsp90 as an anti-cancer target
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Figure 1. Chemical Structures of GM,
17AAG, RD, and the Designed PU Class of
Hsp90 Inhibitors and Its Representative,
PU24FCl
cannot be fully explored because of limitations of the cific binding to the N-terminal pocket of Hsp90 [24]. We
mentally distilled these requirements and designed theexistent inhibitors. To address that, we have developed
a family of novel small molecules that potently and selec- molecular class (PU class) illustrated in Figure 1 [25].
Rational changes in the variables X1, X2, and X3 led totively inhibit Hsp90. We show here that one of these
agents, PU24FCl, is highly specific for tumor Hsp90 and the development of PU24FCl (Figure 1) [26]. PU24FCl is
a representative of this class and is by no means theretains similar potency against a broad range of tumors
in concordance with its inhibitory activity of tumor most potent. In its design, empirical rules for solubility
and cell permeability [27] and bioavailability [28] wereHsp90. We also show that the agent manifests its anti-
cancer activities via degradation of Hsp90 client proteins additionally considered.
involved in tumor growth and survival, tumor-specific
transformation, inhibition of cancer cell growth, delay PU24FCl Is Highly Specific for Tumor Hsp90
of cell cycle progression, and induction of morphologi- In order to probe the affinity and specificity of PU24FCl
cal and functional changes and apoptosis and that these for Hsp90, we tested its ability to compete with GM for
occur at similar doses in all tested tumor types. binding to Hsp90 from tumor cells and also from normal
tissues and organs. We used a homogeneous fluores-
cence polarization assay that can measure real-timeResults and Discussions
interactions of cellular Hsp90 with the inhibitors. The
apparent affinity of PU24FCl for tumor Hsp90 from sev-Design of the PU Class and Its Representative
Lead Compound, PU24FCl eral cellular lysates was relatively similar (an average
relative binding affinity [EC50] value of the six measuredThe N-terminal region of Hsp90 possesses a distinctive
ATP/ADP binding pocket that is conserved from bacteria transformed cell lines of 0.22 0.06 M was calculated;
Figures 2A and 2B). Although the agent bound tightlyto mammals but is not present in other molecular chap-
erones [17]. When bound to the pocket, ATP and ADP to Hsp90 found in transformed cells (breast cancer cell
lines MCF-7, MDA-MB-468, and SKBr3, chronic myeloidadopt a C-shaped conformation found in other members
of the superfamily of proteins called GHKL ATPases leukemia cell line K562, and small cell lung cancers NCI-
N417 and NCI-H69 are presented), its affinity for normal(G  DNA gyrase B, H  Hsp90, K  histidine kinase,
L  MutL) but not observed in the high-affinity ATP/ cell-Hsp90 was at least 10- (brain, pancreas and lung)
to 50-fold lower (heart, kidney, and liver). Interestingly,ADP binding sites [18–20]. Unlike protein kinases, which
bind ATP/ADP with high affinity, Hsp90 binds these nu- PU24FCl’s affinity for Hsp90 present in normal tissue
was not only lower but also much more variable thancleotides with low affinity and has weak ATPase activity
[21–23]. Thus, due to the unique structure of this pocket, for transformed cells (an average EC50 value for the six
measured organs of 8.8  7.6 M was calculated) (Fig-an Hsp90 ligand has a priori a high chance for being
specific. ure 2B). We were also able to confirm the previously
reported higher affinity of 17AAG for tumor Hsp90 [8].We have previously defined the requirements for spe-
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Figure 2. PU24FCl’s Potencies in Inhibiting Tumor Hsp90, Arresting the Growth of Tumor Cells, and Inducing the Degradation of Hsp90 Client
Proteins Are Similar for All Tested Cell Lines
Normal tissue is 10-fold more resistant to PU24FCl’s effects.
(A) The apparent affinity of PU24FCl for Hsp90 from several cell lysates was examined by a fluorescence polarization (FP) method that
measures the ability of the agent to compete fluorescently labeled GM for Hsp90 binding.
(B) Relative binding affinity values (EC50) obtained from FP measurements were determined, and data were presented.
(C) Effect of PU24FCl on the proliferation of a panel of transformed and normal cells. Cells were treated with drugs or vehicle for 72 hr as
described in the Experimental Procedures. Determined IC50 values are presented in (D).
(D) PU24FCl induces the degradation of Hsp90 client proteins involved in tumor cell growth and survival and tumor-specific carcinogenesis
at doses correlating with its ability to induce tumor growth arrest. Cells were treated with drugs or vehicle for 24 hr (for IC50 protein degradation)
and 72 hr (for IC50 growth inhibition) as described in the Experimental Procedures, and proteins were analyzed by Western blot.
The EC50 values of 17AAG and GM for Hsp90 from sev- homologs are similar, we have evaluated PU24FCl and
17AAG for their effects on the well-characterized, single-eral tumor cells were determined as follows: 14  4 and
58.5  20 nM in MCF-7, 39.8  1.3 and 38.3  9.4 nM strand, DNA-stimulated ATP-hydrolytic activity of E. coli
MutL [30, 31]. MutL ATPase activity was relatively insen-in SKBr3, and 59  7 and 37.5  14 nM in MDA-MB-
468, respectively. We tested GM for binding to Hsp90 sitive to inhibition by these agents at concentrations as
high as 5 mM. Previously, 17AAG has been reported tofrom brain and obtained an EC50 of 850  40 nM (in
concordance with the 400 nM reported for 17AAG [8]). bind with nanomolar affinity to ADE2 SAICAR purine
synthetase, an enzyme involved in purine metabolic pro-Our results do not corroborate the previous finding that
tumor Hsp90 from Her2-overexpressing cells (i.e., cessing. The consequences of this effect are not com-
pletely understood, but it may be the cause of someSKBr3) confers a higher affinity for 17AAG than Hsp90
found in other cancer cells [8]. We also found 17AAG in vivo toxicities of the drug. PU24FCl did not inhibit
ADE2 enzyme activity at concentrations as high as 1 mMto be actively and potently binding to tumor Hsp90 from
the SCLC cell lines NCI-H69 (EC50 of 15  5 nM) and (V.J. Davisson, personal communication; determined
IC50  2.2 mM). PU24FCl was also inert against a panelNCI-N417 (EC50 of 49  10 nM). When compared to
SKBr3, these tumors are at least 100 times more resis- of kinases (Akt, Her2, Src, and EGFR) at concentrations
as high as 100 M.tant to the anti-cancer actions of this drug. Thus, we
cannot substantiate a direct link between Hsp90 affinity
and cellular potency in the ansamycin class of com- PU24FCl Equivalently Affects Multiple Aspects
of Transformation via Potent and Selectivepounds and propose that other factors may be responsi-
ble for the highly variant response of tumor cells to Inhibition of Tumor Hsp90 Activity
Inhibition of Cell Growth17AAG [16, 29].
MutL is another mammalian GHKL member and is a We evaluated the in vitro growth-inhibitory properties
of PU24FCl against a broad panel of cancer cell linesprotein involved in mismatch repair [20, 30, 31]. Because
the ATPase centers of bacterial and eukaryotic MutL and two normal epithelial cells. Breast, prostate, acute
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Figure 3. The Effects of PU24FCl on Cell Cycle Progression Are Specific to Cell Type but Occur at Similar Concentrations for All Tested
Cancer Cell Lines, in Correlation with Its Other Hsp90-Dependent Activities
(A and B) Treatment of SKBr3 cells with PU24FCl induces a G1 arrest (A), whereas in MDA-MB-468 cells arrest occurred in G2/M (B). Cells
were treated for 72 hr with 10 M PU24FCl and stained with ethidium bromide before FACS analysis, as described in the Experimental
Procedures.
(C) MCF-7 cells undergo morphological (left panel) and functional differentiation (right panel, induction of MFGM protein is presented) when
they are treated with PU24FCl. Cells were treated for 48 hr with the indicated drug concentrations, and MFGM was detected with a mouse
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myeloid leukemia (AML), acute promyelocytic leukemia, induced most cells to undergo growth arrest in G1 (Fig-
ure 3A), but others underwent arrest in G2/M (Figurechronic myeloid leukemia (CML), colon, small cell lung
cancer (SCLC), non-small cell lung cancer (NSCLC), and 3B). The ability of the agent to block cells in the cell cycle
was concentration dependent, with effects starting atneuroblastoma cell lines and a vulvar squamous cell line
were treated with PU24FCl for 72 hr, and the effects on 1 M and reaching a maximum at 10 M (Figure 3E) in
agreement with its tumor Hsp90-related effects. G1cell viability were determined. PU24FCl inhibited cell
proliferation and retained similar activity in all cancer cell block in PU24FCl-treated cells was followed by morpho-
logical and functional differentiation (Figure 3C). MCF-7lines tested. The IC50 values calculated after exposure to
PU24FCl ranged from 2 to 7 M (Figures 2C and 2D). breast cancer cells flattened, increased in size, and
gained distinctive cellular boundaries upon treatmentThe effects of PU24FCl appeared to be cytostatic in
most tested cancer cell lines but cytotoxic in Her2-over- with PU24FCl (Figure 3C). Additionally, these cells un-
derwent functional differentiation and reversal of trans-expressing cells (i.e., SKBr3 and BT-474, breast), Rb-
defective cells (i.e., MDA-MB-468, breast and NCI-N417, formation in the presence of the drug, as demonstrated
by an induction of milk fat globule membrane proteinSCLC) and in a bcr-abl-driven CML cell line (K562)
(Figure 3A). By contrast to transformed cells, normal (MFGM) [33] (Figure 3C). Another example of a cell line
that differentiated upon PU24FCl addition is K562, aprostate epithelial cells (PrEC) (IC50  43.5  5.3 M)
and human renal proximal tubular epithelial (RPTEC) chronic myeloid leukemic cell line. GPA is a differentia-
tion marker selectively expressed on the cell surface of(IC5063.5  3.5 M) were 1 log more resistant to the
effects of PU24FCl on growth (Figure 2C), consistent erythroblast or erythroleukemia cells [34]. Treatment of
K562 with PU24FCl caused a dramatic increase of GPA-with the 10- to 50-fold-higher affinity of this agent for
tumor versus normal tissue Hsp90 (Figures 2A and 2B). expressing K562 cells (Figure 3F) at concentrations of
PU24FCl above the growth inhibitory IC50 for this cellPU24FCl retained activity in Rb-defective cancer cells.
In these cells, such as SCLC cell lines (i.e., NCI-H69, NCI- line. At such concentrations of RD, only a maximal 20%
GPA induction was reported [35]. A tumor cell subsetN417) and certain breast cancer cells, such as MDA-MB-
468, 17AAG is almost 2 log less sensitive than in most including all of those with defective Rb function (i.e.,
MDA-MB-468, NCI-N417, and NCI-H69), was resistantother cell lines (D.S., unpublished results and [33]). The
cause of lack of potency in these cells is not Hsp90 to induction of G1 block by PU24FCl and was blocked
in mitosis (Figure 3D). The appearance of mitotic nucleidependent because the agent potently inhibits Hsp90
from these tumors (see above) and the phenomenon is in the Rb-defective breast cancer cell line MDA-MB-468
occurred below 5 M (Figure 3F), again in correlationnot observed with PU24FCl.
Degradation of Hsp90 Client Proteins Involved with other anti-cancer effects of the agent in MDA-MB-
468 (Figures 2C and 2D).in Cell Growth and Survival
and Tumor-Specific Transformation Induction of Apoptosis
Cell cycle arrest by PU24FCl was followed by apoptosis.The effects of PU24FCl on growth were correlated with
its effects on Hsp90 client proteins. These proteins (i.e., The degree of apoptosis was cell type dependent (Figure
4A) but, as observed in Figure 4B, occurred at agentHer2, cMet, Raf-1, Akt, ER, mutant AR, mutant p53, and
Bcr-Abl) are thought to be involved in the dysregulated concentrations that produce all other Hsp90-related
anti-cancer effects of PU24FCl. A significant increasegrowth potential and survival of tumor cells and to drive
or contribute to transformation in many tumor types. in the number of apoptotic nuclei was observed in Her2-
overexpressing (i.e., SKBr3; 19%) and Rb-defective (i.e.,Their levels 24 hr after treatment were determined by
Western blot (Figure 2D). Degradation of these Hsp90 MDA-MB-468 and NCI-N417; 44% and 35%, respec-
tively) cells at 72 hr after treatment.client proteins occurred at similar concentrations in the
panel of cancer cells tested, in concordance with the
similar affinity of the drug for the chaperone in these In Vivo Effects of PU24FCl—Accumulation
of Drug in Tumors Leadstumor cells (Figure 2A and data not shown). A significant
reduction was observed for most Hsp90 client proteins to Anti-Cancer-Effective Concentrations
Pharmacokinetic Analysisas early as 8 hr after treatment, whereas no changes in
PI3K (p85 unit) and -actin, proteins not chaperoned by The plasma concentration-time profile of PU24FCl after
intraperitoneal (IP) and intravenous (IV) administrationHsp90, were observed (data not shown).
Arrest of the Cell Cycle by PU24FCl Is Specific was determined. PU24FCl concentrations declined in
an exponential fashion with a rapid absorption and dis-to Cell Type but Occurs at Similar Doses
in All Transformed Cell Lines tribution (Figure 5A). A 70 mg/kg IV and IP dose resulted
in maximum plasma concentrations of 27.4  5.9 g/mlTo evaluate the effect of PU24FCl on cell cycle progres-
sion, we tested a panel of tumor cell lines. The agent (63.1  1.4 M) and 5.2  0.9 g/ml (11.8  0.2 M),
primary antibody and rhodamine-labeled secondary antibodies. Nuclear DNA was stained with DAPI. Results were visualized, imaged, and
quantified under confocal microscopy for immunofluorescence and under a light microscope for measurement of morphology change.
(D) The Rb-defective cell line MDA-MD-468 undergoes mitotic block when treated with PU24FCl. After a 24 hr treatment with vehicle or 5 M
PU24FCl, cells were stained with an anti--tubulin antibody as well as 1 g/ml DAPI. Results were visualized, imaged, and quantified under
confocal microscopy.
(E and F) Arrest in the cell cycle and induction of differentiation by PU24FCl are specific to cell type but occur at similar doses in all tested
cell lines. (E) The increase in the number of mitotic cells (MDA-MB-468), GPA-expressing cells (K562), and MFGM-expressing cells (MCF-7)
is presented as a function of PU24FCl concentration. See Experimental Procedures for more details.
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Figure 4. Cell-Specific Induction of Apoptosis by PU24FCl Occurs at Doses that Are in Correlation with Its Other Anti-Cancer Effects
(A) A cell cycle block in PU24FCl (10 M)-treated cells is followed by apoptosis as determined by FACS analysis (%SubG1) and PARP cleavage
(presented for SKBr3 cells). Cells were harvested at the indicated time periods and stained with ethidium bromide for FACS analysis, and
PARP cleavage was analyzed by Western blot.
(B) A dose-dependent profile for induction of apoptosis in the SCLC cell line NCI-N417 by PU24FCl is presented. Figures portray data for a
representative experiment. Analyses were reproduced at least twice.
which decreased to 0.6  0.1 g/ml (1.3  0.2 M) and and Raf-1 kinases and the transmembrane tyrosine ki-
nases Her2 and Her3, that are involved in the dysregu-0.3 0.1 g/ml (0.7 0.05 M) 4 hr after administration,
respectively. The calculated apparent volumes (2.84 lated growth and survival potential of MCF-7. When
administered intraperitoneally, PU24FCl exhibited aL·kg1 for IV and 13.55 L·kg1 for IP) suggest that the
agent is rapidly distributed after administration. There dose-dependent effect on these Hsp90 client proteins,
with no significant increase in benefit after 200 mg/kgwas no significant difference in the mean area-under-
curve (AUC) values after IV and IP doses (561.8 (Figure 5C). One dose of 200 mg/kg PU24FCl caused a
significant depletion of receptor tyrosine kinases (Her2,g·min·ml1 and 420.5 g·min·ml1), resulting in an ab-
solute bioavailability value (for IP administration) of ap- Her3, and Her4) as well as degradation and inactivation
of Akt and Raf-1 in MCF-7 tumor xenografts, with aproximately 75%. A long-term follow-up of PU24FCl dis-
tribution (200 mg/kg IP) suggested that, although the consistent relationship observed between its tumor ac-
cumulation profile and its effect on Hsp90 client proteinsagent is quickly cleared from blood and normal tissue
(brain and liver are presented), it is accumulated in tumor (Figures 5B and 5D). In contrast to 17AAG administra-
tion, no induction of Hsp70 was observed in tumors attissue with a maximum peak of 14.4 M recorded 24 hr
after administration (Figure 5B). An AUC6–48 hr of 221.6 the indicated times and doses (Figures 5C, 5D, and 5F).
This is a somewhat surprising observation when oneM·min·ml1 was observed for tumor tissue, suggesting
that the in vitro effective dose of 10 M (IC90 for most considers that, when it is administered in tissue culture
to MCF-7 cells, PU24FCl does induce Hsp70 levels. Itcancer cells) was maintained in tumors for approxi-
mately 10 hr (20–30 hr after administration). The AUC6–48 hr is not clear what the significance of Hsp70 induction in
tumors might be, but it has been suggested that in-values for blood and normal tissue were recorded as
0.98 M·min·ml1 for serum, 8.9 M·min·ml1 for liver, creased Hsp70 levels could interfere with the apoptotic
potential of Hsp90 inhibitors [37]. Similar pharmacody-and 0.3 M·min·ml1 for brain. The highest concentra-
tions in these tissues were 0.06, 0.67, and 0.01 M, namic profile of PU24FCl was observed in mice bearing
BT-474 breast cancer xenograft tumors, suggesting thatrespectively, with values declining sharply after 12 hr.
These values suggest that in the interval of 6–48 hr after the in vivo effects of the agent may not be restricted to
one tumor type and that wide-range targeting of onco-administration, PU24FCl is mostly distributed to tumors
(226, 25, and 753 times more than in blood, liver, and genic transformation may also be achieved in vivo (Fig-
ure 5F). Our results also suggest that the broad-rangebrain, respectively). They also hint to breakdown and
clearance of the drug by the hepatic system after long- anti-tumor activity should occur at similar doses, in con-
cordance with this drug’s affinity for tumor Hsp90. Theterm presence in the body. The accumulation of
PU24FCl in tumors is consistent with this agent’s higher in vivo degradation of Hsp90 client proteins by PU24FCl
may translate to the usefulness of this agent or moreaffinity for tumor versus normal tissue Hsp90 (Figure 2).
Pharmacodynamic Analysis potent agents of this class in several malignancies. The
transmembrane tyrosine kinases whose degradation isTo probe the efficacy and safety of PU24FCl as an Hsp90
inhibitor in vivo, we used mice bearing MCF-7 breast induced by PU24FCl include Her2, Her3, and Her4 (Fig-
ures 5C, 5D, and 5F). The overexpression of these recep-cancer xenograft tumors. When compared to Her2-over-
expressing breast cancer cell lines, MCF-7 shows only tors has been associated with aggressive malignancies
[38] and several therapeutic strategies targeting the re-a modest response to 17AAG and is one of the cancer
cell lines that evades apoptosis after Hsp90 inhibition ceptors are now in various stages of clinical develop-
ment [39]. These strategies act to block the activationor other pharmacological interferences ([32, 36]; Figure
4A). As pharmacodynamic markers, we followed the ef- or to inhibit the activity of the kinases (i.e., Herceptin
and Iressa). “Kinase-dead” receptors can still functionfect of PU24FCl on Hsp90 client proteins, such as Akt
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Figure 5. Analysis of PU24FCl In Vivo Administration
The high affinity of PU24FCl for tumor Hsp90 leads to accumulation in tumors with rapid clearance from normal tissue.
(A and B) Pharmacokinetic analysis of PU24FCl. (A) Early distribution (0 to 4 hr): mean plasma concentrations of PU24FCl versus time after
single IP and IV bolus administration of 70 mg/kg PU24FCl to mice. The agent’s concentration in serum was monitored from 0 to 4 hr after
administration and showed rapid adsorption and distribution.
(B) Late distribution (6 to 48 hr): one dose of PU24FCl was administered intraperiotneally to MCF-7 (200 mg/kg) tumor-bearing mice for the
indicated time periods. Mice were sacrificed, and tumors, organs, and serum were harvested. Drug distribution in tissue and serum was
analyzed by LC-MS. In tumors, PU24FCl accumulated to concentrations found in vitro and induced all of its Hsp90-dependent anti-cancer
effects while being rapidly cleared from organs.
(C–F) Pharmacodynamic effects of PU24FCl. (C) The effect of PU24FCl on Hsp90 clients is dose dependent. PU24FCl was administered
intraperitoneally or by PO to MCF-7 tumor-bearing mice at the indicated doses. Mice were sacrificed at 8 hr (for IP) and 24 hr (for PO), and
tumors were harvested. Tumors were processed, and protein levels were analyzed by Western blot. Data were presented as percent control 
protein expression in treated mice/protein expression in control mice*100 and plotted against administered dose of PU24FCl. (D and F)
Pharmacologically relevant concentrations can be achieved and maintained in several tumor types. One IP dose of PU24FCl was administered
to MCF-7 (200 mg/kg) (D) and BT-474 (300 mg/kg) (F) tumor-bearing mice for the indicated time periods. Mice were sacrificed, and tumors
were harvested (drug distribution in MCF-7 tumors is presented in panel [B]). Tumors were processed, and Hsp90 client protein levels were
analyzed by Western blot. (E) Alternate-day administration of 200 mg/kg PU24FCl to MCF-7 tumor-bearing mice resulted in anti-tumor activity
(approximately 70% inhibition) without visible toxicities. Mice (n5) were treated for the indicated time period with an intraperitoneally
administered dose, and tumor volume was measured as presented in the Experimental Procedures.
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as a substrate for other receptors and non-receptor ki- mality may be insufficient in reversing transformation
and would be limited to use in a small subset of can-nases and thus act as a docking protein capable of
signaling. Thus, a more significant therapeutic outcome cers. It has been suggested that one potential way to
circumvent this problem is to target the machinery thatmay result from degrading these oncoproteins via Hsp90
inhibition [40]. We have shown Akt and Raf-1 to be addi- allows most cancer cells to function with the burden of
abnormalities they carry: the chaperone Hsp90. Wetional in vivo targets of PU24FCl (Figures 5C, 5D, and
5F). The Raf-MAPK pathway regulates cell proliferation, have developed and validated a new generation of
potent inhibitors that, by specific tumor Hsp90 inhibi-and differentiation and interference with the activity of
proteins in this pathway is believed to be effective in tion, can unvaryingly target a broad range of cancers.
As a result of their comprehensive targeting of onco-cancer treatment [41]. In addition, Akt is an important
regulator of cell proliferation and survival [42], and ele- genic transformation, these agents might represent
compelling new therapeutics.vated Akt activity has been observed in tumors with
mutations in PTEN, one of the most frequently mutated
Experimental Procedurestumor suppressor genes [43, 44].
Based on our in vitro data, effects of PU24FCl on
Syntheses of PU24FCl and GM-BODIPY were described elsewhere
Hsp90 protein levels occurred alongside with growth [26, 45].
arrest and induction of apoptosis at concentrations
ranging from 1 to 10 M. It is thus reasonable to believe Hsp90 Competition Assay
Fluorescence polarization measurements [45] were performed onthat these doses may have effects in vivo on other can-
an Analyst AD instrument (Molecular Devices, Sunnyvale, CA). Mea-cer hallmarks dependent on Hsp90. Because a 200
surements were taken in black 96-well microtiter plates (Corningmg/kg dose administered intraperitoneally resulted in
#3650). The assay buffer (HFB) contained 20 mM HEPES (K) (pH1–15 M drug accumulated in tumors for at least 20 hr
7.3), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, and 0.01% NP40.
(Figure 5B), we tested this dose for inhibition of tumor Before each use, 0.1 mg/ml bovine  globulin (BGG) (Panvera Corpo-
growth. An alternate-day schedule of 200 mg/kg ration, Madison, WI) and 2 mM DTT (Fisher Biotech, Fair Lawn, NJ)
were freshly added. For preparation of cell lysates, cellular mem-PU24FCl (no other dose or scheduling regiment was
branes were frozen at70C so that membranes would be ruptured,tried, and no efforts were made for optimization) was
and the cellular extract was dissolved in HFB with added proteasefurther studied for single-agent anti-tumor efficacy in
and phosphotase inhibitors. Organs were harvested from a healthythe MCF-7 xenograft model. The study was conducted
mouse and homogenized in HFB. Saturation curves in which GM-
for 30 days to result in a 72% reduction in tumor burden BODIPY (5 nM) was treated with increasing amounts of cellular
in the treated group compared to the control (Figure 5E). lysates were recorded. The amount of lysate that resulted in polar-
ization (mP) readings corresponding to 20 nM recombinant Hsp90No weight loss or visible internal change upon dissection
was chosen for the competition study. For the competition studies,was observed in the treated group (data not shown).
each well contained 5 nM fluorescent GM, cellular lysate (amountsTo explore whether this class of Hsp90 inhibitors
as determined above and normalized to total Hsp90 as determinedcould be ultimately tailored for oral administration, we
by Western blot analysis with Hsp90 purified from HeLa cells [Stress-
tested the oral availability of PU24FCl. One dose of gen# SPP-770] as a standard) and tested inhibitor (initial stock in
500,750 and1000 mg/kg PU24FCl was administered DMSO) in a final volume of 100 l. For liver, the amount of GM-
BODIPY had to be increased because of high autofluorescence ofby oral gavage (PO) to mice bearing MCF-7 xenograft
the liver homogenate. The plate was left on a shaker at 4C for 7tumors. Twenty-four hours after treatment, animals were
hr, and the FP values in mP were recorded. EC50 values were deter-sacrificed, tumors were analyzed, and a dose-depen-
mined to be equal to the competitor concentration that displaceddent decline in Hsp90 client proteins was observed; the
50% of the fluorescent GM.
results were comparable to those obtained in the IP
studies with this agent (Figure 5C). It is possible, in light MutL ATPase Assay
of the cytostatic effect of Hsp90 inhibitors against some ATP hydrolysis was determined at 37C in reactions (20 l) con-
taining 20 mM Tris-HCl (pH 8.0), 90 mM KCl, 1 mM DTT, 4 Mtumors, that repetitive dosing will be required, and oral
d(T)100 (molecules), and 0.8 M MutL. The effect of the inhibitorsavailability may thus be an important factor for a suc-
on ATP hydrolytic activity was determined by the addition of 5 mMcessful clinical candidate of this action.
PU24FCl or 17AAG. Hydrolysis was initiated by the addition of
In conclusion, our results define a novel class of “drug- [32P]ATP·(Mg2	) to prewarmed reactions to give a final concentration
like” agents that target with similar potencies a broad of 0.3 mM. At 10 min intervals, 2 l samples were taken and
spectrum of malignancies via specific inhibition of tumor quenched with 50 l of 0.5 M EDTA (pH 8.0). The extent of ATP
hydrolysis was determined by chromatography of 1 l of theHsp90. As such, their activity would not be limited to a
quenched sample on polyethyleneiminecellulose plates (EM Sci-small subset of cancers. Administered alone or in combi-
ence) that were developed in 0.3 M K3PO4 (pH 7.0). Dried plates werenation with other agents, they would represent a novel
phosphorimaged overnight and optically scanned with a STORM
therapeutic approach for the treatment of cancer pa- imager system, and data were analyzed with Imagequant software
tients with advanced disease. (Molecular Dynamics). Initial steady-state rates of hydrolysis were
determined by least-squares analysis of the linear portion of the
progress curve. One hundred percent activity corresponds to 8 mol
ADT/min/mol of MutL. Inhibition of a panel of kinases was evaluatedSignificance
at Panlabs Pharmacology Services.
A recent trend in cancer therapy has been to develop
Cell Cultureagents that “target” a single molecular alteration.
The human cancer cell lines MCF-7, SKBr3, MDA-MB-468, BT-474,
However, most tumors are characterized by multiple NCI-H69, NCI-N417, TSUPr1, Colo205, A549, A431, K562, and
growth-regulatory alterations, and these are specific LNCaP were a gift from Dr. Neal Rosen, and Kasumi-1 and NB4
were from Dr. Steve Nimer (MSKCC). Cells were maintained in a 1:1to the type of tumor. Thus, drugs targeting one abnor-
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mixture of DME:F12 supplemented with 2 mM glutamine, 50 units/ immunofluorescence, the slides were washed twice with ice-cold
PBS and fixed with methanol and acetone solution (1:1) for 15 s.ml penicillin, 50 units/ml streptomycin, and 5%–10% heat-inacti-
vated fetal bovine serum (Gemini Bioproducts) and incubated at Fixed monolayers were washed with distilled water and blocked
with 5% BSA in PBS solution. After blocking took place, cells were37C, 5% CO2.
incubated with the primary antibody (anti-MFMG, Chemicon, 1:100
in 5% BSA in PBS) at 37C and washed three times with 1% BSAGrowth Assays
in PBS; incubation with a rhodamine-labeled secondary antibodyGrowth inhibition studies were performed with the sulforhodamine
followed for 1 hr at 37C.B assay as previously described [16]. In summary, experimental
Mitotic Blockcultures were plated in microtiter plates (Nunc). One column of wells
Harvested cells were washed in PBS, fixed in methanol for 20 minwas left without cells to serve as the blank control. Cells were
at 20C, washed again in PBS, and blocked for 30 min in PBSallowed to attach overnight. The following day, growth medium hav-
with 5% BSA. Cells were stained first with mouse monoclonal anti-ing either drug or DMSO at twice the desired initial concentration
-tubulin (Sigma) and then with rhodamine-conjugated anti-mousewas added to the plate in triplicate and was serially diluted at a 1:1
antibody as well as 1 g/ml DAPI. Results were visualized, imaged,ratio in the microtiter plate. After 72 hr of growth, the cell number
and quantified under confocal microscopy.in treated versus control wells was estimated after treatment with
10% trichloroacetic acid and staining with 0.4% sulforhodamine B
in 1% acetic acid. The IC50 was calculated as the drug concentration Animal Studies
that inhibits cell growth by 50% compared with control growth. Four- to 6-week-old nu/nu athymic female mice were obtained from
Normal prostate epithelial cells (PrEC) and human renal proximal the National Cancer Institute-Frederick Cancer Center and main-
tubular epithelial (RPTEC) cells were purchased preseeded in 96- tained in ventilated caging. Experiments were carried out under an
well plates (Clonetics, CC-0088 and 3190, respectively). Upon re- Institutional Animal Care and Use Committee-approved protocol,
ceipt, cells were placed in a humidified incubator at 37C, 5% CO2 and institutional guidelines for the proper and humane use of ani-
and allowed to equilibrate for 3 hr. Media were removed by suction mals in research were followed. MCF-7 (5 
 106 cells) or BT-474
and replaced with fresh media provided by the manufacturer. Cells (1 
 107 cells) human mammary tumor cells were subcutaneously
were then treated with either drugs or DMSO for 72 hr, and the IC50 implanted in the right flank of nu/nu athymic mice via a 20 gauge
values were determined as described above. needle and allowed to grow. Three days prior to tumor inoculation,
0.72 mg 17-estradiol 90-day release pellets (Innovative Research
Protein Assays of America, Sarasota, FL) were implanted subcutaneously in the left
Cells were grown to 60%–70% confluence and exposed to drugs or flank. For pharmacodynamic studies, tumors were allowed to reach
DMSO vehicle for the indicated time periods. Lysates were prepared 6–8 mm in diameter before treatment. Before administration, a solu-
with 50 mM Tris (pH 7.4) and either 2% SDS or 1% NP-40 lysis tion of PU24FCl was prepared at the desired concentration in 50 l
buffer. Protein concentrations were determined with the BCA kit vehicle (PBS:DMSO:EtOH at 1:1:1 ratio). At sacrifice, plasma, tumor,
(Pierce) according to the manufacturer’s instructions. Protein ly- liver, and brain tissue were collected. A gross necropsy was per-
sates (20–100 g) were electrophoretically resolved on denaturing formed on all mice. In experiments designed to define the pharmaco-
7% SDS-PAGE, transferred to nitrocellulose membrane, and probed dynamic effects of PU24FCl on Hsp90 client protein expression,
with the following primary antibodies: anti-Her2 (C-18), anti-Her3 mice (n  2) with established tumors were treated with 200 mg/kg
(C-17), anti-Her4 (C-18), anti-Raf-1, hMet (C-28) (Santa Cruz), anti- PU24FCl or with vehicle alone. At the time of sacrifice, serum was
ER (Stressgen Bioreagents), anti--actin (Sigma), anti-PI3K (p85) collected, and tumors and normal tissue were flash frozen. For pro-
(Upstate Biotechnologies), anti-p53 (NeoMarkers), anti-cAbl (Onco- tein analysis, tumors were homogenized in SDS lysis buffer (50
gene), anti-AR (Pharmingen), anti-Akt, and anti-pAkt (Cell Signaling). mM Tris [pH 7.4], 2% SDS). For pharmacokinetic analysis, plasma
Membranes were then incubated with a 1:5000 dilution of a peroxi- samples were obtained by retro-orbital puncture at the indicated
dase-conjugated corresponding secondary antibody. ECL (Amer- times after the IP or IV administration of 70 mg/kg PU24FCl or
sham Life Science, Inc.) was performed according to the manufac- vehicle alone. For quantitative HPLC analysis, tissue samples were
turer’s instructions. Blots were visualized by autoradiography, and homogenized in EtOH:H2O (2:1) solution at a 1:3 w/v ratio. Concen-
the protein was quantified with BioRad Gel Doc 1000 software. trations of PU24FCl were determined by high-performance liquid
chromatography-mass spectrometry (HPLC-MS) at the Analytical
Core Facility of the Memorial Sloan-Kettering Cancer Center. TheFlow Cytometry
Agilent 1100 series (Agilent Instruments, Palo Alto, CA) was usedAnalysis of intracellular DNA content was performed on a FACScan
for HPLC analysis with Sorbax SB-C8 column (i.d. 4 
 80 mm). Theflow cytometer (Becton Dickinson). Cells were trypsinized, har-
mobile phase consisted of acetonitrile (ACN) and 0.1% formic acidvested, and stained with 25 g/ml EtBr in a citric buffer. Cells (20 

in water, and analysis was performed under gradient conditions105/sample) were analyzed at a rate of 100–200 cells/s. Data were
from 45% to 65% ACN for 10 min and then 65% ACN for an additionalanalyzed with FlowJo software, and the percentage of cells in all
5 min at a flow rate of 0.4 ml/min. Serum samples were dissolvedcell cycle phases was determined as a ratio of the fluorescent area
1:2 (v/v) in MeOH, incubated at 4C overnight, and centrifuged, andof the appropriate peaks to the total fluorescent area.
20 l of supernatant was injected into the column. The PU24FCl
peak appeared at 7.5 min. For growth studies, tumors were allowedDifferentiation of K562
to reach 5 mm in diameter, and then animals were randomly dividedExpression of the erythroid-specific surface marker GPA was deter-
into the treatment groups (n 5). Mice were treated every other daymined by a previously described method [35]. In brief, 1 
 106 cells
with a dose of 200 mg/kg and then monitored for tumor progression.were incubated at 4C for 30 min with 100 l (10 g/ml) of mouse
Tumor dimensions were measured every 2 days with vernier cali-antihuman GPA monoclonal antibody (Pharmingen). Next, cells were
pers, and tumor volumes were calculated with the formula /6 
washed twice with ice-cold PBS to remove unbound antibody, re-
larger diameter 
 (smaller diameter)2. Mice with established tumorssuspended in 10g/ml of FITC-labeled goat anti-mouse IgG (Wako),
of 4–5 mm in diameter were selected for study (n  5 per treatmentand incubated at 4C for 30 min in the dark. The cells were then
group). While on therapy, all mice received Augmentin (Amoxicillin/washed twice with ice-cold PBS and resuspended in 1% paraformal-
Clavulanate potassium; SmithKline Beecham) in their drinking water.dehyde in PBS (pH 7.4). Mouse IgG1 (Wako) was used as an isotype-
Mice were sacrificed by CO2 euthanasia.matched negative control for each sample. 10 
 103 events were
analyzed for each sample by FACScan (Becton Dickinson).
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